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Hedgehog (Hh) signaling during development and in
postembryonic tissues requires activation of the 7TM
oncoprotein Smoothened (Smo) by mechanisms that
may involve endogenous lipidic modulators. Exoge-
nous Smo ligands previously identified include the
plant sterol cyclopamine (and its therapeutically use-
ful synthetic mimics) and hydroxylated cholesterol
derivatives (oxysterols); Smo is also highly sensitive
to cellular sterol levels. The relationships between
these effects are unclear because the relevant Smo
structural determinants are unknown. We identify
the conserved extracellular cysteine-rich domain
(CRD) as the site of action for oxysterols on Smo,
involving residues structurally analogous to those
contacting the Wnt lipid adduct in the homologous
Frizzled CRD; this modulatory effect is distinct from
that of cyclopamine mimics, from Hh-mediated
regulation, and from the permissive action of cellular
sterol pools. These results imply that Hh pathway
activity is sensitive to lipid binding at several Smo
sites, suggesting mechanisms for tuning by multiple
physiological inputs.
INTRODUCTION
The Hedgehog (Hh) signal transduction pathway controls
numerous aspects of embryonic patterning and regeneration of
postembryonic tissues (Beachy et al., 2004; Varjosalo and Tai-
pale, 2008). Insufficient Hh signaling can result in a range of birth
defects including holoprosencephaly (Beachy et al., 2004;
Muenke and Beachy, 2000; Varjosalo and Taipale, 2008), while
inappropriate pathway activity is linked to human malignancies
such as basal cell carcinoma and medulloblastoma (Teglund
and Toftga˚rd, 2010). Despite intensive study, the mechanisms346 Developmental Cell 26, 346–357, August 26, 2013 ª2013 Elseviethat ensure proper reception and transduction of the Hh signal
remain largely mysterious (Lum and Beachy, 2004; Rohatgi and
Scott, 2007). Pathway activation is initiated by binding of the
cholesterol-modified Hh morphogen (Mann and Beachy, 2004)
to its receptor, the transporter-like tumor suppressor Patched1
(Ptch1). Hh-induced inactivation of Ptch1 releases the inhibition
of Smoothened (Smo), a seven-transmembrane (7TM) oncopro-
tein with extended extracellular and cytoplasmic termini (Lum
and Beachy, 2004; Rohatgi and Scott, 2007). Activated Smo
then accumulates in the vertebrate primary cilium, ultimately trig-
gering transcription of Hh target genes via activation of Gli tran-
scription factors (Lum and Beachy, 2004; Rohatgi et al., 2007).
A key question in the study of Hh signal transduction concerns
the physiological mechanisms that influence Smo activity in
pathway-responsive cells. One leading model hypothesizes
that Smo is regulated by an endogenous lipidicmodulator whose
availability is controlled by Ptch1 transport activity (Eaton, 2008;
Hausmann et al., 2009; Taipale et al., 2002). Indeed, a remarkable
arrayof exogenous smallmolecules impingesonvertebrateSmo,
including the plant-derived sterol cyclopamine and its synthetic
mimics (Chen et al., 2002a, 2002b), which are finding therapeutic
uses as pathway antagonists (Von Hoff et al., 2009; Rudin et al.,
2009; Tang et al., 2012; Teglund and Toftga˚rd, 2010). Smo can
also be activated by noncellular hydroxylated cholesterol deriva-
tives such as 20(S)-hydroxycholesterol (20(S)-OHC) (Corcoran
and Scott, 2006; Dwyer et al., 2007; Nachtergaele et al., 2012).
Furthermore, Smo-mediated signal transduction is highly sensi-
tive to genetic or pharmacological depletion of endogenous
cellular sterols (Cooper et al., 2003; Corcoran and Scott, 2006)
(Figure 1A). It is tempting to postulate that all of these sterols
act on Smo via shared structural mechanisms that might also
be employed by endogenous Ptch-regulated ligands. However,
the mechanisms of small-molecule action and the relationship
of these mechanisms to the modulatory effects of Ptch1 activity
remain unclear, and in most cases the relevant Smo structural
determinants have not been precisely delineated.
Although the involvement of heterotrimeric G proteins in Smo-
mediated transduction is debated (Ayers and The´rond, 2010),
Smo and the related group of Frizzled (Fz) Wnt receptors clearlyr Inc.
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within the larger group of 7TMproteins. A recent crystal structure
of the humanSmoheptahelical domain in complexwith a cyclop-
amine mimic confirmed its seven-pass topology and revealed a
ligand-binding site enclosed by a cage of transmembrane helices
and the interior surfaces of extracellular loops and connected to
the aqueous extracellular environment via a narrow tunnel (Wang
et al., 2013). This membrane-bounded pocket, a canonical loca-
tion for ligand-binding in GPCRs (Lagerstro¨m and Schio¨th, 2008;
Venkatakrishnan et al., 2013), was initially defined in Smo by
studies with cyclopamine (Chen et al., 2002a, 2002b) and is the
apparent site of action for pathway agonists or antagonists that
compete for cyclopamine binding to Smo (cyclopamine mimics).
Apart from the presence of a canonical 7TM domain, several
structural features distinguish Smo and Fz from the GPCRs typi-
cally found in physiologic signaling systems and, despite
numerous apparent differences between the modes of ligand
reception and intracellular signal transduction in their respective
developmental pathways, the existence of common Smo and Fz
structural elements implies that some aspects of their activation
mechanisms may be fundamentally related. One hallmark of the
Smo and Fz subfamily is the N-terminal cysteine-rich domain
(CRD), a three-helix bundle stabilized by five stereotyped disul-
fide bonds, which is biochemically, crystallographically, and
genetically established in Fz receptors as its site of interaction
with the diffusible Wnt ligand (Bhanot et al., 1996; Cadigan
et al., 1998; Janda et al., 2012; Povelones and Nusse, 2005).
The Smo CRD is also highly conserved (Ayers and The´rond,
2010; Huangfu and Anderson, 2006; Ingham et al., 2011), and
missense mutations in this domain reduce Hh signaling during
development (Aanstad et al., 2009; Chen and Struhl, 1998;
Nakano et al., 2004). In contrast to Fz, however, Smo plays no
known role as a site for morphogen reception, as this function
is performed in the Hh pathway by Ptch1 and coreceptors
(Beachy et al., 2010). Thus, the biochemical function of the
Smo CRD remains unknown and any potential connection with
the corresponding domain in Fz remains unexplored.
In this study, we identify the Smo CRD as the major binding
site for action of several oxysterols, including 20(S)-OHC and
two additional cellular modulators, 7-keto-25- and 7-keto-
27-hydroxycholesterol (7-keto-25-OHC, 7-keto-27-OHC). Oxy-
sterol binding to Smo involves residues structurally analogous
to those contacting the Wnt lipid adduct in the homologous Fz
CRD (Janda et al., 2012). Oxysterol activation furthermore is
distinct from modulation by cyclopamine or its mimics, from
Ptch1-mediated regulation, and from the permissive action of
endogenous sterol pools in Hh-responsive cells. These results
suggest that Smo activation involves a conformational rear-
rangement modulated by lipidic molecules acting at multiple
distinct sites within the extracellular and heptahelical domains
and further suggest the possibility that Smo activity is tunable
by multiple physiological inputs.
RESULTS
An Intact CRD Is Required for Smo Activation
by Oxysterols
Oxysterol activation of EBI2/GPR183 (Epstein-Barr virus-
induced molecule 2), a class A GPCR, is triggered in immuneDevelopcells by binding of 7a-25- or 7a-27-hydroxycholesterol (7a-25-
OHC, 7a-27-OHC) to a pocket located within the external half
of themembrane-spanning heptahelical bundle (Benned-Jensen
et al., 2012; Zhang et al., 2012). A similar ligand-binding pocket
exists in Smo, and mutations in this region disrupt the binding
of cyclopamine, of its synthetic mimics, and of certain agonists
(Buonamici et al., 2010; Dijkgraaf et al., 2011). We examined
the pharmacological properties of various Smo sequence alter-
ations using a transcriptional reporter assay of Hh pathway acti-
vation in Smo/ mouse embryonic fibroblasts (MEFs); in these
cells, Smo-dependent pathway activation depends entirely on
Smo exogenously introduced by transfection (Varjosalo et al.,
2006; see also Figure S1A available online), permitting experi-
mental analysis of Smo structure-function relationships. We
found that responsiveness to 20(S)-OHC either alone or in syner-
gistic combination with 22(S)-OHC was not affected by ‘‘cyclop-
amine pocket’’ mutations D477G and E522K, previously shown
to block the effects of one or more cyclopamine-competitive
Smo agonists and antagonists (Figure 1B; Figure S1A). These
results suggest that the heptahelical bundle might not contain
the binding site for modulatory oxysterols, consistent with earlier
studies showing that oxysterols and cyclopamine do not
compete with each other for binding to Smo (Dwyer et al.,
2007; Nachtergaele et al., 2012).
Bioinformatic and structural modeling studies have revealed
an unexpected parallel between the N-terminal CRD of Fz
receptors and the cholesterol- or riboflavin-binding modules
of Niemann-Pick C1 and RBP proteins, respectively (Bazan
and de Sauvage, 2009), suggesting that binding of small lipidic
molecules may be a property of some CRD folds. We therefore
tested whether Smo oxysterol responsiveness was altered upon
deletion of the CRD (SmoDCRD). We found that SmoDCRD
exhibited significant constitutive activity relative to wild-type
(WT) Smo or the cyclopamine pocket mutants (Figure 1B; Fig-
ure S1A). However, the resulting SmoDCRD basal activity was
wholly resistant to induction by 20(S)-OHC and partially resis-
tant to induction by ShhN (Figure 1B). Despite loss of oxysterol
modulation, SmoDCRD remained fully responsive to agonists
(SAG and purmorphamine) and antagonists (KAAD-cyclop-
amine and GDC-0449) that bind within the transmembrane
domain (Figure 1B; Figure S1A). SmoDCRD thus displays a
selective defect in stimulation by ShhN or oxysterols that is
nearly opposite to the pharmacological profile of the D477G
and E522K mutants. We noted no significant differences
between WT and SmoDCRD in their accumulation in primary
cilia upon transient overexpression in NIH 3T3 cells (Figure 1C;
Figure S1B), consistent with previous measurements of the
ciliary localization of CRD-deleted forms of Smo in cell lines or
in embryos (Aanstad et al., 2009; Dorn et al., 2012). In quantita-
tive enzyme fusion-based titration assays of Smo expression,
we noted no dramatic effects of CRD deletion on expression
level; while a modest (30%) increase in SmoDCRD protein
was detected at the lowest level of plasmid transfection relative
to its WT counterpart, this effect was not consistent across a
range of transfection ratios and is not sufficient to account for
the dramatic functional effects of CRD deletion on basal- or
oxysterol-induced activity (Figure 1D; Table S1). The functional
defect of SmoDCRD in response to ShhN or oxysterol stimula-
tion thus is not due to alterations in Smo protein levels, defectsmental Cell 26, 346–357, August 26, 2013 ª2013 Elsevier Inc. 347
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Figure 1. Distinct Structural Determinants
Required for Regulation of Smo by Ptch
and by Endogenous and Exogenous
Ligands
(A) Schematic diagram of Hh-pathway compo-
nents showing multiple regulatory mechanisms
that impinge on Smo, including Hh antagonism of
Ptch-mediated suppression, direct modulation by
cyclopamine and related small-molecule agonists
and antagonists, activation by oxysterols, and a
requirement for cholesterol.
(B) Luciferase activity in Smo/ mouse embry-
onic fibroblasts (MEFs) cotransfected with Gli-
luciferase reporter plasmids and cDNAs encoding
wild-type (WT) mSmo or the E522K or DCRD
mutants following treatment with control or
ShhN-conditioned medium (red and green bars,
respectively); 20(S)-OHC (10 mM, blue bars); SAG
(200 nM), purmorphamine (2.5 mM), or ShhN-
conditioned medium with KAAD-cyclopamine
(KAADcyc, 300 nM) (black bars). Error bars
represent SDs (n = 3 independent transfections
per data point). A summary of the experiment is
shown; the complete data set is presented in
Figure S1A.
(C) Ciliary localization of Myc-taggedWT orDCRD
Smo constructs was examined in fixed NIH 3T3
cells stained with antibodies against acetylated
tubulin (red) or the Myc epitope (green); nuclei
were visualized with DAPI (blue). Small panels to
the right of selected images display shifted over-
lays of the acetylated tubulin and Myc channels.
See Figure S1B for quantification.
(D) Quantification of WT Smo and Smo DCRD
protein in transfected Smo/ MEFs over a range
of expression levels using C-terminal fusions to
Renilla luciferase. The x axis indicates percent-
age of Smo cDNA transfected into each well,
while the y axis indicates Renilla measure-
ment, normalized to a control secreted alkaline
phosphatase (SEAP) construct; replicates and
error bars are as in (B).
See also Figure S1 and Table S1.
Developmental Cell
Multiple Lipid Binding Sites on Smoothenedin ciliary entry, or in the ability of SmoDCRD to engage down-
stream transduction machinery.
The CRD Is Required for Oxysterol Stimulation but
Exerts Indirect Effects on Basal and Hh-Induced Smo
Activity States
The phenotype of SmoDCRD raises the possibility that an intact
CRD is critical for modulation by oxysterols as well as by Hh-
mediated Ptch1 inactivation. However, comparison between
WT and CRD-deleted Smo is complicated by the latter’s abnor-
mally high basal activity, which could in principle mask the
activating effects of ShhN or oxysterols. To more conclusively
test whether the CRD mediates the regulatory action of Ptch
on Smo, as suggested by the partial loss of SmoDCRD response
to ShhN stimulation, we examined the effect of elevated levels of
Ptch1 on basal and Hh-induced activation of this Smo deletion
mutant. Ptch1 overexpression has previously been shown to
reduce the basal activity of WT Smo or of the fully constitutively
active oncogenic mutant SmoA1 (corresponding to the SmoM2348 Developmental Cell 26, 346–357, August 26, 2013 ª2013 Elsevieallele in human basal cell carcinoma) (Taipale et al., 2000,
2002). In each of these cases, Smo constitutive activity is
strongly suppressed by substoichiometric amounts of Ptch1,
and Smo activity is restored by treatment with Hh protein
(Taipale et al., 2002), illustrating that the underlying inhibitory
effects are dependent on Ptch1 activity rather than nonspecific
consequences of protein overexpression. An insensitivity of
SmoDCRD basal activity to Ptch1 coexpression would be
consistent with a direct role for the CRD in mediating Ptch1
effects on Smo. In contrast, if the basal activity of SmoDCRD
diminishes upon Ptch coexpression, then the Ptch1 regulatory
mechanism must be intact in this mutant and any observed
reduction in ShhN-induced activation is indirect, likely allosteric
in nature.We observed in transfected Smo/MEFs that, likeWT
Smo or SmoA1, the basal activity of SmoDCRD was potently
suppressed by Ptch1 coexpression and its activity was restored
in the presence of ShhN or SAG (Figures 2B and 2C). To confirm
this result in an independent cell line, we tested whether Ptch1
coexpression could reduce the basal activity of SmoDCRDr Inc.
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Figure 2. The Smo CRD Is Required for
Modulation by Oxysterols and Indirectly
Affects Ptch1-Mediated Regulation
(A) Basal (non-ShhN-stimulated) Gli-luciferase
activity in NIH 3T3 cells transfected with the indi-
cated cDNA constructs in the absence (red) or
presence (orange) of cotransfected Ptch1 (25%
DNA for Smo WT and DCRD; 5% DNA for the
constitutively active SmoA1 construct).
(B) Gli-luciferase assay in Smo/ MEFs revealed
thatSmoA1activity is inducedbyoxysterols (20(S)-
OHC + 22(S)-OHC, 5 mM each) upon suppression
of its basal activity by coexpression of Ptch1.
(C) Gli-luciferase assay in Smo/ MEFs trans-
fected with WT or DCRD Smo, in the presence or
absence of overexpressed mPtch1, following
treatment with control or ShhN-conditioned
medium, SAG (200 nM), 20(S)-OHC (10 mM), or
20(S)-OHC + 22(S)-OHC (5 mM each). Comparable
Ptch1-mediated suppression was demonstrated
by transfecting increased WT Smo cDNA to
compensate for the higher DCRD Smo basal
activity as described in the Experimental
Procedures. Error bars represent SDs (n = 3
independent transfections per data point).
See also Table S1.
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express endogenousWT Smo, their low basal Hh pathway activ-
ity in transcriptional reporter assays permits measurements of
constitutive activity in complementary DNA (cDNA) transfection
experiments (Taipale et al., 2000, 2002). We indeed observed
suppression of SmoDCRD basal activity in NIH 3T3 cells (Fig-
ure 2A), similar to our results in Smo/ MEFs. Thus, our Ptch1
coexpression studies show that although CRD deletion compro-
mises full activation of Smo upon Hh-mediated release of Ptch1
inhibition, this domain is not the major site on Smo for Hh-sensi-
tive regulation by Ptch1.
Although SmoDCRD remains sensitive to Ptch1 regulatory
effects, the ability of Ptch1 coexpression to reduce the basal
activity of SmoDCRD provides an opportunity to test whether
the observed loss of oxysterol sensitivity (Figure 1B) could be a
secondary consequenceof themutant’s enhancedbasal activity.
Unlike the effect of ShhN or SAG treatment, however, suppres-
sion of SmoDCRD activity by Ptch1 was not reversed by 20(S)-
OHC either alone or in the presence of 22(S)-OHC (Figure 2C).
This result illustrates that an intact CRD is absolutely required
for Smo activation by oxysterols. In contrast, WT Smo or onco-
genic SmoA1 clearly retains oxysterol sensitivity even in the
presence of elevated Ptch1 levels (Figures 2B and 2C). Our
Ptch1 coexpression experiments thus confirm that the Smo
CRD is essential for the effects of oxysterols on Smo. BecauseDevelopmental Cell 26, 346–357the phenotype of CRD deletion with re-
gard to basal and ShhN-induced activity
can be partially reversed under experi-
mental conditions of Ptch1 overexpres-
sion, any role for the CRD in basal or
ShhN-induced activity probably stems
from indirect, allosteric effects on other
parts of Smo. In contrast, the same exper-
imental conditions fail to restore oxysterolsensitivity to SmoDCRD, arguing that the CRDmust play a direct
and indispensable role in the oxysterol activation process.
The Smo CRD Binds Oxysterols via Residues
Structurally Analogous to the Wnt Lipid-Binding Groove
on the Fz CRD
To test whether the CRD serves as the physical site of interaction
for 20(S)-OHC, we employed a binding assay that utilizes a
20(S)-OHC alkyne derivative (20(S)-yne) immobilized on mag-
netic beads. In this assay, consistent with previous results
(Nachtergaele et al., 2012), we found that WT Smo expressed
in HEK293 cells and solubilized in n-dodecyl-b-D-maltoside
(DDM) robustly binds to the 20(S)-yne affinity resin and that the
interaction is specific as it is competed by excess 20(S)-OHC
(Figure 3A). In contrast, the level of binding to mSmoDCRD
was dramatically reduced, and no competition was observed
with free 20(S)-OHC, indicating that any residual binding is
nonspecific (Figure 3A). We also tested binding of a C-terminal
truncation (SmoDCT) and found, as previously noted for binding
of cyclopamine to this mutant protein (Chen et al., 2002a), that
binding was less efficient as compared to WT Smo; binding to
immobilized 20(S)-yne was nevertheless potently inhibited by
20(S)-OHC (Figure 3A), indicating that deletion of the Smo
CRD, but not the Smo cytoplasmic region, eliminates specific
binding to 20(S)-OHC in vitro., August 26, 2013 ª2013 Elsevier Inc. 349
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Figure 3. The Smo CRD Directly Binds
Oxysterols
(A) Detergent-solubilized membranes from
HEK293FT cells transfected with Myc-tagged WT
Smo, DCRD, or DCT deletion mutants were incu-
bated with control or 20(S)-yne affinity resin in the
presence of 50 mM 20(S)-OHC competitor or
vehicle, as indicated in the table. After washing,
bound protein was eluted and analyzed by
immunoblotting (‘‘bound’’). The DCRD and DCT
mutants bound less efficiently than WT Smo to
20(S)-yne matrix; analysis of 3.33 equivalents of
bound material nevertheless revealed specific
binding for DCT, but not DCRD.
(B) A similar experiment as in (A) with Myc-tagged
WT mFz7 or an mFz7-mSmoNT chimera.
(C) Experiments as above, but using concentrated
conditioned medium (no added detergent) from
293S-GnT1 cells infected with BacMam virus
encoding Protein C-tagged mSmoNT-3CS or
mFz7 CRD constructs.
In these and all subsequent blots the migration of
molecular weight markers (in kDa) is indicated to
the left. Results are representative of multiple in-
dependent experiments.
See also Figure S2.
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20(S)-OHC binding, we examined a chimera in which the mouse
Fz7 (mFz7) N-terminal domain (including its CRD) was replaced
with that of mouse Smo (mFz7-mSmoNT). We observed a low
level of nonspecific binding toWTmFz7 but substantially greater
binding to mFz7-mSmoNT, which appears specific as it was
dramatically reduced in the presence of free 20(S)-OHC (Fig-
ure 3B). We also examined binding to a secreted protein
comprising the SmoCRD and the short linker sequence just prior
to the start of TM1, with three linker region cysteines altered to
prevent adventitious aggregation (Figure S2). The resulting pro-
tein, mSmoNT-3CS, bound specifically to 20(S)-OHC, whereas
a similar soluble CRD construct from mFz7 displayed only
nonspecific binding (Figure 3C). These experiments indicate
that the core determinants of specific 20(S)-OHC binding are
contained within the N-terminal module of Smo rather than in
its transmembrane or cytoplasmic portions.
Recent crystallographic studies of the mFz8 CRD in complex
with its acylated Wnt ligand revealed an unexpected mode of
Wnt binding that resembles a hand grasping two distinct sites
on opposite surfaces of the CRD (Janda et al., 2012) (Figure 4A).
Site 1 of the CRD comprises a hydrophobic pocket formed by
side chains from CRD a helices that engulf the Wnt palmitoleyl
‘‘thumb,’’ with little contribution to binding from Wnt amino350 Developmental Cell 26, 346–357, August 26, 2013 ª2013 Elsevier Inc.acid side chains. Site 2 in contrast is a
shallow depression that engages amino
acid side chains on the Wnt protein’s
‘‘forefinger’’ (Figure 4A). We hypothesized
that the Smo CRD might bind to oxyster-
ols in a manner resembling the interaction
between the Fz8 CRD and the Wnt palmi-
toleoyl adduct. Accordingly, we tested
the effects of alterations in CRD site 1
and site 2 residues (alignment in Fig-ure S3) on specific binding to 20(S)-OHC, focusing our analysis
on the slower-migrating fully glycosylated postendoplasmic
reticulum forms (Chen et al., 2002a) of each altered protein.
Alanine substitutions of CRD site 2 residues Y89, P128, and
K137 E139 N140 E144 (KENE) had no qualitative effect on
specific binding of 20(S)-OHC to Smo (Figure 4B). In contrast,
the site 1 substitutions R165A P168A and W113A G115A
L116A (WGL) blocked specific 20(S)-OHC binding, whether in
the context of the Smo protein (Figure 4B) or in the mFz7-
mSmoNT chimera (Figure 4C). We conclude that Smo CRD
site 1 residues are essential for interaction with 20(S)-OHC,
whereas site 2 residues are largely dispensable.
Activation of Smo by Naturally Occurring Cellular
Oxysterols
Although 20(S)-OHC is capable of activating Smo when supplied
exogenously to Hh-responsive cells, the physiological relevance
of this lipid in the context of Hh pathway stimulation is not clear,
as no sterol hydroxylase has been reported to produce 20(S)-
OHC in cells. Furthermore, although 20(S)-OHC could easily
be identified when added to NIH 3T3 cell cultures (Figures
S4A–S4C; Table S1), we and others have been unable to detect
endogenous 20(S)-OHC in these cells (Roberg-Larsen et al.,
2012). These observations prompted a search for naturally
Figure 4. A Conserved CRD Lipid-Binding
Interface in Smo and Fz CRDs
(A) Structure of a complex between XWnt8 and the
mFz8 CRD as reported by Garcia and colleagues
(Janda et al., 2012) (orange and blue, respectively;
Protein Data Bank code 4F0A) showing the Wnt
lipid adduct (red) and the location of CRD site 1
(yellow) and site 2 (purple) residues. In the image at
right, a magnified view of the Fz8 CRD site 1 is
presented to highlight residues that contact the
lipid. See sequence alignment in Figure S3.
(B) In vitro binding assay as in Figures 2A and 2B
with the indicated Myc-tagged Smo constructs
transfected into HEK293FT cells. Site 1 and 2
mutants are indicated in yellow and purple to
correspond to the structural model. Low and high
exposures of the same input and bound fractions
are also provided, and arrows above and below
the 100 kDa marker indicate the positions of the
immature endoplasmic reticulum (ER)-resident
and fully glycosylated post-ER forms of WT Smo.
Note that this assay sensitively detects specific
20(S)-OHC binding to low amounts of post-ER
Smo, as seen for WT Smo diluted 33-fold in a
control membrane extract and for the site 2mutant
Y89A; no specific binding, however, is observed
for the site 1 WGL mutant, which exhibits similar
post-ER levels (see ‘‘input’’ panel).
(C) Effect of the site 1 WGL mutation on oxysterol
binding to Myc-tagged mFz7-mSmoNT chimera.
See also Figure S3.
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Multiple Lipid Binding Sites on Smoothenedoccurring oxysterols that modulate Smo activity. 7-keto-27-
OHC has been identified as a metabolic intermediate in the elim-
ination of 7-ketocholesterol from tissues, which in turn is formed
via oxidation of an immediate cholesterol precursor by cyto-
chrome P450 (CYP) 7A1. 7-keto-27-OHC is detectable in
extracts from retinal pigment epithelial (RPE) cells and can also
be formed in vitro by incubating 7-ketocholesterol with RPE
homogenates or recombinant sterol 27-hydroxylase (CYP27A1)
(Heo et al., 2011) (Figure 5A). In experiments with Hh-pathway
responsive NIH 3T3 cells, we found that 7-keto-27-OHC could
activate the Hh transcriptional reporter to approximately the
same level as ShhN, while the structurally related oxysterols
7a-27-dihydroxycholesterol (7a-27-OHC) and 7a-27-dihydroxy-
cholestenone (7a-27-OH-3-one) were substantially less active
(Figure 5B). 7-keto-27-OHC also produced additive activation
of the reporter when combined with ShhN (Figure 5B), and like
20(S)-OHC it synergizedwith SAGor with 22(S)-OHC (Figure 5C).
In a survey of other oxysterols for Smo-modulatory capacity,
we found that 7-keto-25-OHC, another potential metabolite ofDevelopmental Cell 26, 346–3577-ketocholesterol, also produced sub-
stantial Gli-luciferase reporter activation
when combined with 22(S)-OHC (Figures
S4D and S4E). As with other Hh pathway
modulators acting directly on Smo, 7-
keto-27-OHC induced the accumulation
of endogenous Smo in the primary cilia
of NIH 3T3 cells (Figure 5D; Figure S4F),
and its activity in transcriptional reporter
assays was abolished by cyclopamine(Figure S4G). We also found that 7-keto-27-OHC and 7-keto-
25-OHC specifically block binding of Smo to immobilized
20(S)-yne in vitro (Figure 5E). Using Smo/ MEFs to test the
effect of mutations in the Smo extracellular domain or cyclop-
amine pocket on activation by 7-keto-27-OHC, we found that
the 7-keto oxysterol failed to activate SmoDCRD (Figure 5F).
Taken together, these results suggest that 7-keto-27-OHC and
7-keto-25-OHC, like 20(S)-OHC, act on Smo via direct binding
to the CRD.
Multiple Distinct Sterol Effects Converge
on the Hh Pathway at the Level of Smo
Human cholesterol synthesis disorders, such as Smith-Lemli-
Opitz syndrome, combined with cultured cell studies have
established a link between cellular sterols and Smo activation
in response to Hh stimulation (Cooper et al., 2003). This require-
ment for sterols maps genetically to Smo (Cooper et al., 2003)
and a relationship to the modulatory effects of oxysterols
has been suggested (Corcoran and Scott, 2006; Nachtergaele, August 26, 2013 ª2013 Elsevier Inc. 351
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Figure 5. Naturally Occurring Oxysterols
Modulate Smo Activity via CRD Engage-
ment
(A) Schematic diagram of sterol biosynthetic
pathways leading to the formation of 7-keto-
25-OHC and 7-keto-27-OHC (in red). Enzyme
names are indicated in black italics; solid
and dashed arrows represent experimentally
verified or proposed biosynthetic steps, res-
pectively. CYP7A1, cholesterol 7a-hydroxy-
lase; CYP27A1, sterol 27-hydroxylase; CH25H,
cholesterol 25-hydroxylase. For comparison, the
structure of the noncellular 20(S)-OHC is shown
in blue.
(B) Gli-luciferase activity in Hh-pathway-respon-
sive NIH 3T3 Shh-LIGHT2 cells was measured
following treatment with the indicated sterols
either alone (blue) or in combination with ShhN-
conditioned medium (green).
(C) Concentration-response analysis of Gli-lucif-
erase activity in Shh-LIGHT2 cells treated with
7-keto-27-OHC alone (red), in combination with
22(S)-OHC (5 mM, blue), or with a threshold
concentration of SAG (1 nM, black). Statistical
significance (Student’s t test): *p < 0.01,
**p < 0.001.
(D) Ciliary accumulation of endogenous Smo
in NIH 3T3 cells treated with control or
ShhN-conditioned medium or 7-keto-27-OHC;
the inactive oxysterol 7a-27-OH-3-one serves
as a negative control. Fixed cells were ana-
lyzed by immunofluorescence using antibodies
against Smo (green) or acetylated tubulin
(red) with DAPI counterstain (blue). Shifted
overlays of Smo and acetylated tubulin stains
are displayed as small panels to the right of
selected images. See Figure S4F for image
quantification.
(E) Binding of WT Smo to immobilized 20(S)-yne
was tested as in Figure 2A, using the indicated
sterols as competitors (all at 50 mM except
20(S)-yne, at 100 mM). Additional sterols identified
in this study as Smo modulators are shown in
red, while inactive analogs are shown in black. For
comparison, 20(S)-OHC and related derivatives
are shown in blue.
(F) Gli-luciferase assay in Smo/MEFs transfected with the indicated Smo and Ptch1 constructs and stimulated with control (red) or ShhN-conditioned medium
(green), 100 nM SAG (black), or 5 mM 7-keto-27-OHC (blue).
Error bars for (B), (C), and (F) represent SDs (n = 3 independent culture wells or transfections per data point). See also Figure S4 and Tables S1 and S2.
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Multiple Lipid Binding Sites on Smoothenedet al., 2012), but the molecular basis of this role for sterols is not
known. This sterol requirement can be experimentally demon-
strated by b-cyclodextrin- and statin-mediated sterol depletion
and consequent loss of transcriptional reporter activation (Fig-
ure 6A). We also observed that sterol depletion blocks ShhN-
induced ciliary Smo accumulation (Figure 6B; Figure S5). The
effects of sterol depletion are reversed by replenishment of cells
with cholesterol or the more water-soluble cholesteryl hemisuc-
cinate (CHS), but not by a synthetic enantiomer of cholesterol
(ent-cholesterol) (Belani and Rychnovsky, 2008) whose stereo-
chemistry is reversed at every chiral center (Figure 6A). The
failure of ent-cholesterol to rescue Hh response indicates a ste-
reospecific site of action for cholesterol and is consistent with a
direct Smo-cholesterol interaction rather than an effect on mem-
brane structure and fluidity. However, we note that this result352 Developmental Cell 26, 346–357, August 26, 2013 ª2013 Elseviedoes not rule out the possibility of relevant physical interactions
between cholesterol and chiral membrane lipids.
Our identification of the CRD as the major site of action on
Smo for activating oxysterols provides an opportunity to ask
whether the requirement of an intact sterol synthesis pathway
for Smo function derives from an analogous CRD-lipid inter-
action. Despite its unresponsiveness to activating oxysterols,
we found that SmoDCRD remained sensitive to sterol depletion
(Figure 6C). Sensitivity to sterol depletion is also retainedwith the
E522K alteration of the cyclopamine pocket (Figure 6C), and in
the context of stimulation by the agonists SAG and purmorph-
amine (Figure 6D). In testing whether this role for cholesterol is
linked to oxysterol modulatory effects, we also found that CHS
failed to compete for specific binding to immobilized 20(S)-
OHC (Figure 5E). These data together show that the permissiver Inc.
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ts Figure 6. The Smo Activation State Is Regu-
lated by Multiple Distinct Sterol Effects
(A) NIH 3T3 cells were transfected with Gli-
luciferase reporter plasmids and stimulated with
ShhN-conditioned medium in combination with
the indicated exogenous sterols (at 100 mM)
following endogenous sterol depletion (with
methyl-b-CD plus lovastatin as described in
Experimental Procedures).
(B) Ciliary accumulation of endogenous Smo in
ShhN-stimulated NIH 3T3 cells following depletion
of endogenous sterols (as described in A) and
subsequent rescue with exogenous cholesterol.
See Figure S5 for image quantification.
(C) In Smo/MEFs transfected with the indicated
Smo constructs, Gli-luciferase activity induced
by ShhN stimulation was measured under mock-
treated (red) or sterol-depleted (blue) conditions
as in (A).
(D) In NIH 3T3 cells, endogenous sterol deple-
tion (‘‘depleted’’) reduced Gli-luciferase activity
induced by treatment with ShhN-conditioned
medium, SAG (500 nM), or purmorphamine
(2.5 mM), as compared to mock-depleted controls
(‘‘mock’’).
Error bars in all luciferase assays represent SDs
(n = 3 independent transfections per data point).
See also Figure S5 and Table S1.
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Multiple Lipid Binding Sites on Smoothenedeffect of cholesterol on Smo is mediated by structural determi-
nants that lie outside the CRD oxysterol-binding site and are
likely distinct from the cyclopamine pocket (Figure 7). Further-
more, the requirement of intact cellular cholesterol pools for effi-
cient Smo function is mechanistically independent of any Smo
activation that occurs via oxysterol-CRD interactions.
DISCUSSION
A direct role for cholesterol in Smomodulation echoes the struc-
turally defined interactions of sterols with other 7TM proteins
(Burger et al., 2000).Modulatory ligand binding near the extracel-
lular portion of the heptahelical bundle is also a common feature
of class A GPCRs (Venkatakrishnan et al., 2013), analogous to
the Smo cyclopamine pocket, and several metabotropic neuro-
transmitter receptors bind their ligands through structured extra-
cellular domains (Lagerstro¨m and Schio¨th, 2008), reminiscent of
our findings with the Smo CRD. Strikingly, each of these three
Smo modulatory sites can be occupied by distinct types of
steroidal ligands. The identification of these multiple sites andDevelopmental Cell 26, 346–357their modulators should facilitate struc-
tural elucidation of active and inactive
full-length Smo conformations through
ligand-mediated stabilization strategies
that have accelerated the crystallo-
graphic analysis of GPCR activation (Ven-
katakrishnan et al., 2013). Within the
Smo/Fz subfamily, it is intriguing that the
Wnt lipid adduct is recognized by site 1
of the Fz CRD and that a corresponding
portion of the Smo CRD mediates oxy-sterol binding and regulation. Although sterols and fatty acids
are structurally unrelated, a predicted swap in the Smo CRD
disulfide bond pattern with respect to Fz CRDs (J.F.B., data
not shown; Figure S3) suggests possible alterations in the
dimensions of the Smo CRD hydrophobic groove. Photoaffinity
labeling and crystallographic experiments of full-length Smo or
its isolated CRDwill more precisely define the structural determi-
nants of oxysterol interaction in the Smo extracellular domain
and may also identify additional endogenous lipids that bind to
this region.
How does Ptch1 regulate Smo activity? Although an intact
Smo CRD is required for activation by oxysterols, our functional
analysis shows that Ptch1 coexpression restores basal and Hh-
induced activation to SmoDCRD, thereby indicating that this
domain is not the major site of regulation by Ptch1. By similar
reasoning, the ability to dissociate oxysterol action on Smo
from Ptch regulatory effects argues that oxysterols like 20(S)-
OHC or the 7-ketocholesterol derivatives studied here are
unlikely to subserve the regulatory functions of Ptch1 (Figure 2C).
The failure of SmoDCRD to become fully activated in response to, August 26, 2013 ª2013 Elsevier Inc. 353
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Figure 7. Summary Model Indicating Multiple Sterol Modulatory
Effects in Hh Signal Transduction at the Level of mSmo, as well as
Their Binding Determinants
Oxysterols (blue) activate Smo via CRD engagement (hypothetical structural
model of human Smo CRD, with mutations affecting oxysterol binding indi-
cated in blue), while cyclopamine and related anticancer drugs (orange) bind to
a pocket in the extracellular half of the heptahelical domain. Mutations that
affect binding and/or signaling inhibition by cyclopamine and its mimics GDC-
0449 and NVP LDE-225 are displayed in orange; cholesterol (purple) may bind
directly to an allosteric site facing the membrane, as has been shown for other
GPCRs. See also Figure S6.
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Multiple Lipid Binding Sites on SmoothenedHh may point instead to a more indirect facilitative CRD function
in stabilizing an active Smo conformation induced by loss of
Ptch1-mediated repression. The structural basis for such stabi-
lization could be a physical interaction between the CRD and the
extracellular surface of the Smo transmembrane domain (dis-
cussed in more detail below) that could permit the CRD to influ-
ence the conformational equilibrium of the heptahelical bundle,
ensuring low basal activity and high Hh-induced responsive-
ness. This stabilizing effect of the CRD could be independent
of its lipid-binding capacity but still involve an interaction with
the transmembrane domain. Alternatively, the ligand-binding
function of the CRD may be intimately related to its ability to
regulate Smo conformation, under which circumstances one or
more bound lipids (such as oxysterols) would likely serve as co-
factors required for proper basal and Hh-induced Smo activation
but whose availability is not directly controlled by Ptch1 activity.
As another possible, albeit more complex regulatory mecha-
nism, Ptch1 conceivably could act on both the Smo transmem-
brane domain and on the CRD lipid-binding pocket as well.
Future structural and functional investigations, as well as identi-
fication of endogenous Smo ligands, will be required to distin-
guish between these potential mechanisms of Smo regulation.
Ptch1 regulation of Smo involves sequences outside of the
CRD, but the major site of action for Ptch1 on Smo has yet to
be delineated. The Smo transmembrane ligand-binding cavity,
which is the site of interaction for cyclopamine and its mimics,
has been proposed to bind an endogenous ligand whose
availability is controlled by Ptch1. In this regard, however, it
is interesting that point mutants in the Smo transmembrane
and extracellular loop (ECL) domains, defined by their ability to
disrupt action of one or more cyclopamine mimics (some devel-354 Developmental Cell 26, 346–357, August 26, 2013 ª2013 Elsevieoped as anticancer drugs), display essentially normal basal and
Hh-induced activity (Figure 1C; Figure S6; Buonamici et al.,
2010; Dijkgraaf et al., 2011; Kim et al., 2013; Yauch et al.,
2009), raising the possibility that Ptch1 acts on Smo via mecha-
nisms that do not involve modulation of small-molecule ligand
binding within the cyclopamine pocket. Such a mechanism
could involve lipids binding to additional sites on Smo that are
yet to be identified. Another plausible scenario is that endoge-
nous Smo ligands regulated by Ptch1 activity engage the cyclop-
amine pocket in a manner that is insensitive to these previously
described mutations, although we note from examination of the
recent X-ray structure of the Smo 7TM domain in complex with
an anticancer drug (Figures S6A and 6B) that the residues high-
lighted by drug-resistant mutations collectively cover a signifi-
cant portion of the ligand-binding surface. Delineation of the
Ptch1 site of action on Smo ultimately awaits identification of
Ptch-regulated bioactive small molecules (steroidal or other-
wise) as well as more extensive mutagenesis of the crystallo-
graphically resolved heptahelical ligand-binding site.
In any case, the similar roles for lipid interaction in these CRDs
defined here and recently confirmed by another study (Nedelcu
et al., 2013) raise the possibility that Smo and Fz activation
may share some features, despite divergent modes of protein
ligand recognition and intracellular signal transduction of the bio-
logically distinct Hh and Wnt signaling pathways. In activation of
its canonical pathway, theWnt protein ligand nucleates a ternary
complex with Fz and low-density lipoprotein receptor-related
protein 5/6, and transduction of this binding event results from
recruitment of cytoplasmic effectors to a newly generated intra-
cellular surface (Clevers and Nusse, 2012). Oxysterol activation
of Smo may similarly proceed through lipid-mediated changes
in protein association, such as the Smo dimerization that has
been reported to depend on CRD integrity (Zhao et al., 2007).
Alternatively, the oxysterol-bound Smo CRD might influence
the conformation and activity state of the heptahelical bundle
by docking with the large Smo ECLs, as occurs with the N-termi-
nal tethered ligand exposed by thrombin cleavage in protease
activated receptor 1 (PAR 1) (Coughlin, 2000). In support of
this idea, point mutations of ECL cysteines lead to increased
basal activation and decreased Hh sensitivity in Drosophila
Smo (Carroll et al., 2012); in fact, one such cysteine substitution
is predicted to break a disulfide bond that tethers ECL1 to the
structured linker region joining the CRD to TM1. This phenotype
is remarkably similar to that resulting from deletion of the mouse
Smo CRD, consistent with the hypothesis that each of these
sequence alterations affects the same regulatory process.
Although the CRD is not present in the recently published crystal
structure of the Smo heptahelical bundle in an inactive confor-
mation (Wang et al., 2013), it is intriguing that the ECLs form a
highly structured ‘‘tower’’ whose external surface could scaffold
an interaction with the CRD, and the observed rigid extension of
the sixth transmembrane helix into ECL3 (see Figure S6B) might
provide a lever arm to translate changes in CRD-ECL interac-
tions to the Smo heptahelical and intracellular domains.
The Smo CRD is highly conserved, and missense mutations in
this domain lead to defects in Hh signaling in vivo (Aanstad et al.,
2009; Chen and Struhl, 1998; Nakano et al., 2004), but the
biochemical function of the CRD in Smo regulation has remained
a mystery. The ability of the Smo CRD to bind oxysterols raisesr Inc.
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Multiple Lipid Binding Sites on Smoothenedthe possibility that this domain may mediate Smo-modulatory
effects of physiologically relevant small molecules; this possibil-
ity is supported by oxysterol response for a range of vertebrate
Smo proteins (data not shown). Indeed, the functional defect
resulting from removal of the Smo CRD (Figure 1B) suggests
that the CRD can strongly affect basal or Hh-stimulated Smo
activity, and future biochemical and genetic studies may delin-
eate roles for 7-keto-25-OHC, 7-keto-27-OHC, or other CRD-
binding lipids in influencing Smo under normal or pathological
conditions. Of particular interest for this mechanism of regula-
tion, the cell-surface accessibility of the Smo N terminus (Denef
et al., 2000; Milenkovic et al., 2009) may permit the CRD to sam-
ple the extracellular milieu, potentially rendering Smo suscepti-
ble to modulation by diffusible messengers such as secreted
hormones and metabolites. In contrast, the influence of Ptch
on Smo is strictly cell autonomous (Briscoe et al., 2001; Chen
and Struhl, 1996), suggestive of a membrane-delimited
biochemical regulatory event. These dual modes of Smo regula-
tion may serve to couple a systemic input with the inherently
local Hh response, tuning Hh pathway output based on feedback
frommetabolic circuits (Teperino et al., 2012) or other aspects of
organismal physiology.
EXPERIMENTAL PROCEDURES
Cell Culture
4C20 Smo/ MEFs (Varjosalo et al., 2006), HEK293FT cells (Life Technolo-
gies), and stably transfected HEK293-ShhN cells (Maity et al., 2005) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS; Omega Scientific) and 1% penicillin/
streptomycin/glutamine. NIH 3T3 cells and stable Shh-LIGHT2 cells were
maintained in DMEM with 1% penicillin/streptomycin/glutamine and 10%
bovine calf serum (HyClone) as previously described (Kim et al., 2010). 293-
Freestyle suspension cells were maintained in 293-Freestyle medium (Invitro-
gen). 293S-GnT1 cells were cultured in pro-293(S)-CDM (Lonza) with 0.1%
FBS (BenchMark, Gemini), 10 mM GlutaMAX, and 0.01% penicillin/strepto-
mycin as previously described (Dukkipati et al., 2008). Spodoptera frugiperda
(Sf9) cells were cultured in Sf900-III (Life Technologies) with 10% FBS (Bench-
Mark, Gemini) and 10 mg/ml gentamicin as previously described (Dukkipati
et al., 2008).
Antibodies, Chemicals, and Small Molecules
The following antibodies were used in this study: anti-acetylated tubulin
(mouse monoclonal, Sigma, T6793, 1:1,000), anti-c-Myc (rabbit polyclonal,
Santa Cruz Biotechnology, A14, 1:1,000), anti-protein C (mouse monoclonal,
Roche, HPC4, 1:400). A previously described polyclonal antibody against
mouse Smo (Kim et al., 2009) was used at 1:1,000. For immunoblotting, horse-
radish peroxidase-conjugated goat anti-rabbit and anti-mouse secondary
antibodies (1:20,000) were from Promega. For immunofluorescence micro-
scopy, Alexa Fluor 488- and 594-conjugated secondary antibodies (Life Tech-
nologies) were used at 1:1,000. Control and ShhN-conditioned medium were
produced fromHEK293-ShhN stable cells as described (Maity et al., 2005) and
diluted 10- to 20-fold for cell treatments. SAG was purchased from Enzo Life
Sciences. Purmorphamine was purchased from VWR Scientific. 20(S)-OHC,
22(S)-OHC, and CHS were purchased from Sigma. Azide-PEG4-NHS ester
was purchased from Click Chemistry Tools. 7-keto-27-OHC and its analogs
were purchased from Avanti Polar Lipids. All other sterols were purchased
from Steraloids. 20(S)-yne was purchased from Cayman Chemical. SiMAG
amine magnetic beads were purchased from Chemicell. Ent-cholesterol was
synthesized as previously described (Belani and Rychnovsky, 2008).
Transfections and Reporter Assays
Shh-LIGHT2, NIH 3T3, and 4C20 Smo/ cells were seeded into 24- or 96-well
plates and transfected with various cDNAs (TransIT 2020, Mirus) along with aDevelopmixture of 83Gli-luciferase and SV40-Renilla plasmids as previously
described (Kim et al., 2009). Transfection mixtures were supplemented with
a GFP expression plasmid to normalize the amount of DNA delivered to
each well. For expression in Smo/ MEFs, transfection mixtures generally
contained 1%–2% (w/w) of each Smo cDNA except in Figures 1D or 2C, where
cells received 1%–50% (w/w) or 1%-10% (w/w) of Smo cDNA as described in
the respective legends. Upon reaching confluency, cells were shifted to
DMEM with 0.5% serum containing ShhN-conditioned medium, agonists, or
antagonists (or appropriate vehicle controls) where indicated and incubated
for 24–48 hr, at which point luciferase activity was measured (Dual Luciferase,
Promega) using a Berthold Centro XS3 luminometer. Depletion of cellular
sterols was performed with 45 min of 8 mM methyl-b-CD extraction followed
by sustained lovastatin (5 mM) treatment as previously described (Kim et al.,
2010). For quantification of Smo-Renilla expression, a secreted alkaline phos-
phatase plasmid (pSEAP-CT) was cotransfected as a normalization control
and the assay (Phospha-Light, Applied Biosystems) was performed as
previously described. HEK293FT cells in 10 cm dishes were transfected with
Lipofectamine 2000 (3.75–7.5 mg DNA per dish) according to the manufac-
turer’s instructions. For BacMam-mediated viral expression in HEK293
suspension cell lines, recombinant baculovirus was produced in Sf9 cells via
cotransfection with linearized baculovirus DNA (Sapphire, Allele Biotech-
nology) using Cellfectin II and amplified as previously described (Dukkipati
et al., 2008); high-titer baculovirus stocks were used to infect log-phase
HEK293 cells for 2–3 days in the presence of 10 mM sodium butyrate.
Immunofluorescence
Indirect immunofluorescence was performed essentially as previously
described. Briefly, NIH 3T3 cells were grown to confluency on coverslips, at
which point they were shifted to low serum medium and incubated overnight
with various treatments as outlined in the main text. The next day, cells were
fixed in 4% paraformaldehyde/PBS (Figure 1) or ice-cold methanol (Figures
5 and 6) and stained with the indicated primary and secondary antibodies
along with DAPI counterstain. After mounting, coverslips were imaged on a
Zeiss LSM 510 laser scanning confocal microscope (Figure 6) or a Leica
SD6000 spinning disc confocal microscope with three blind iterative cycles
of computerized z stack deconvolution using LAS AF software as previously
described (Kim et al., 2009) (Figures 1 and 5).
Preparation of 20(S)-yne Affinity Matrix
20(S)-yne affinity matrix was prepared by a modification of a previous method
(Nachtergaele et al., 2012) using a two-step coupling procedure. A total of
4 mg of SiMAG amine beads was washed into 0.8 ml of high-quality dimethyl-
formamide (DMF) and reacted with 525 nmol azide-PEG4-NHS ester cross-
linker in the presence of 1.05 mmol of triethylamine for 2 hr. After extensive
washing in DMF, the azide-derivatizedmatrix was used for alkyne-azide cyclo-
addition with 350 nmol of 20(S)-yne (stock solution at 10 mM in ethanol) in the
presence of 250 mmol CuSO4-5H2O and 5 mM freshly prepared sodium
ascorbate, The reaction proceeded for 2 hr, after which point the beads
were incubated in acetic anhydride/DMF (2:8 v/v) for several hours to block
any free amine groups. Beads were subsequently washed in DMF and stored
in ethanol (0.8 ml volume) until ready for use. Control resin was prepared in the
same manner but the azide-PEG4-NHS and 20(S)-yne were omitted. Coupling
efficiency was assessed at the azide-alkyne cycloaddition step by thin-layer
chromatography (TLC) of reaction supernatants essentially as described
(Nachtergaele et al., 2012), except that methanol/dichloromethane 1:9 (v/v)
was used as solvent and the TLC plate was visualized by staining in Hanes-
sian’s reagent. Each binding reaction typically employed 20 ml of affinity resin
per 400 ml of solubilized membranes or conditioned medium.
Oxysterol Ligand Affinity Chromatography
Transfected HEK293FT cells were pelleted by low-speed centrifugation and
subjected to hypotonic lysis, membrane isolation, and solubilization in 0.1%
DDM-containing extraction buffer as previously described (Nachtergaele
et al., 2012). A total of 5% of each binding reaction was typically reserved
an ‘‘input’’ fraction, and competitor ligands (or an equivalent amount of vehicle,
either DMSO or ethanol) were preincubated for 1 hr with the solubilized
membranes prior to addition of equilibrated control or 20(S)-yne affinity resin.
Binding was allowed to proceed overnight, after which point the beads weremental Cell 26, 346–357, August 26, 2013 ª2013 Elsevier Inc. 355
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Multiple Lipid Binding Sites on Smoothenedwashed three times in extraction buffer and eluted with SDS-PAGE sample
buffer for 20 min at 37C. For binding studies with secreted extracellular
domains, 20 ml of 0.45 mm filtered conditioned medium from BacMam-
infected HEK293S-GnT1 cells was concentrated 10-fold (Amicon 3 kDa
MWCO centrifugal concentrator) and subjected to ligand affinity chromatog-
raphy as described above, except that cell culture medium (pro-293(S)
CDM, Lonza) with no added detergent was used for the equilibration and
wash steps.
Immunoblotting
Protein samples were separated on Criterion TGX SDS-PAGE gels (Bio-Rad),
transferred to polyvinylidene difluoride membranes, blocked in PBS + 0.1%
Tween-20 with 5% milk, and blotted with the relevant primary and secondary
antibodies. For experiments with protein C-tagged constructs, Tris-buffered
salinewith 1mMCaCl2 was used in place of PBS owing to the Ca
2+-dependent
nature of the antibody-epitope interaction. Membranes were visualized using
an electronic CCD-equipped Chemidoc XRS+ imager (Bio-Rad).
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